Atreca, Inc.
Atreca, Inc. (BCEL): 5 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.0 months
D/E 1.45
Lead: Phase 1
5 candidates
N/A
N/A
A transparent, data-derived signal for Atreca, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.6M
Quarterly Burn
$17.2M
Runway
4.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| apn-122597 | Preclinical |
| apn-346958 | Preclinical |
| apn-497444 | Preclinical |
| atrc-101 | Phase 1 |
| mam01/atrc-501 | Preclinical |
Frequently asked questions
How many drug candidates are in Atreca, Inc.'s pipeline?
Atreca, Inc. (BCEL) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Atreca, Inc.'s lead drug candidate?
Atreca, Inc.'s most advanced tracked candidate is apn-122597 (Preclinical) for multiple cancers.
What is Atreca, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Atreca, Inc. has approximately 4.0 months of cash runway.
Who is the CEO of Atreca, Inc.?
Directors John is the chief executive officer of Atreca, Inc. (BCEL).
Get the full picture on Atreca, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.